 Home > Active Ingredient News > Antitumor Therapy > Lancet Sub-Journal: The magic drug aspirin "re-emerges", can reduce the recurrence of colorectal polyps by more than 60%!

Lancet Sub-Journal: The magic drug aspirin "re-emerges", can reduce the recurrence of colorectal polyps by more than 60%!

 Last Update: 2021-04-13
 Source: Internet
 Author: User

Tags

cancer stage iiia

1 2 dimethoxybenzene

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The evidence that aspirin prevents CRC has been confirmed by many top studies.

Prevention Lancet Aspirin is used to prevent high-risk groups of CRC with genetic predisposition, which can halve the risk of such patients, and the effect can be as long as 10-20 years! Aspirin is used to prevent high-risk groups of CRC with genetic predisposition, which can reduce the risk of such patients by half, and the effect can be as long as 10-20 years!

Familial adenomatous polyposis (FAP) is an autosomal dominant genetic disease caused by mutations in the colon adenomatous polyposis gene (APC).

If fully developed can reach thousands of colorectal adenomas, the risk of colorectal cancer (CRC) can be as high as 100%.

Currently, the only established treatment for FAP patients to prevent CRC is colectomy, which greatly reduces the patient’s quality of life.

This is a randomized, double-blind, placebo-controlled, multi-center trial conducted in 11 centers in Japan, using a 2-to-2 factorial design.

The patients were randomly divided into the following four groups: aspirin (100mg/d) + mesalazine (2g/d), aspirin (100mg/d) + placebo, placebo + mesalazine (2g/d), or double Placebo.

A total of 104 patients were randomly assigned to receive aspirin + placebo (n=52) or mesalazine + placebo (n=52).

Overall, aspirin can reduce the risk of recurrence of colon polyps by 63%.

The most common adverse events were 26 patients received aspirin plus mesalazine has three (12%) grade 1-2 appears on the medsci.

The most common adverse events in patients 26 received aspirin plus mesalazine has three (12%) appear on the 1-2 grade medsci.

Low-dose aspirin can safely inhibit the recurrence of colorectal polyps larger than 5.

references:

Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.